Mesoblast Limited (ASX:MSB)

Market Cap	2.83B
Revenue (ttm)	9.16M
Net Income (ttm)	-167.00M
Shares Out	1.27B
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,950,258
Average Volume	9,699,780
Open	2.240
Previous Close	2.230
Day's Range	2.190 - 2.270
52-Week Range	0.470 - 3.370
Beta	2.13
RSI	45.93
Earnings Date	May 23, 2025

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, whi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 73
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MSB

Financial Performance

In 2024, Mesoblast's revenue was $5.90 million, a decrease of -21.32% compared to the previous year's $7.50 million. Losses were -$87.96 million, 7.41% more than in 2023.

Financial numbers in USD